Pipeline

In this area of cancer metabolism, we are developing novel compounds that target an oxidative stress pathway which is differentially upregulated in cancer cells.

Many studies have been undertaken to examine the differential regulation of NQO1 expression in solid tumors, with the implication that increased protein levels could be selectively targeted through substrates of NQO1. These studies have shown that NQO1 is expressed at elevated levels in a broad range of solid tumors, including pancreatic, breast, and lung cancers.

In addition to cancer, StemPar is also evaluating other therapeutic indications for which SPS-201 could provide clinical benefit. The therapeutic areas under consideration include inflammatory and metabolic disorders, such as rheumatoid arthritis, multiple sclerosis, hypertension, and renal injury. In animal models, NQO1-directed agents have shown potential benefit in treatment of these disorders.

LEAD THERAPEUTIC AREAS:

• Pancreatic cancers
• Breast cancers
• Lung cancers
• Other solid tumors
• Inflammatory and metabolic disorders